Modulation of endothelial organelle size as an antithrombotic strategy.
Francesco FerraroFrancesca PatellaJoana R CostaRobin KettelerJanos Kriston-ViziDaniel F CutlerPublished in: Journal of thrombosis and haemostasis : JTH (2020)
A novel approach to identification of antithrombotic compounds generated a significant number of candidates with the ability to shorten WPBs. In vitro assays of two selected compounds confirm that they inhibit the pro-hemostatic activity of secreted VWF. This set of compounds acting at a very early stage of the hemostatic process could well prove to be a useful adjunct to current antithrombotic therapeutics. Further, in the current SARS-CoV-2 pandemic, with a considerable fraction of critically ill COVID-19 patients affected by hypercoagulability, these WPB size-reducing drugs might also provide welcome therapeutic leads for frontline clinicians and researchers.